3. Kodali S et al clinical Patients with severe, July 2016 ‘Early randomised and echocardiographic symptomatic AS (high surgical registry outcomes after SAPIEN 3 risk or inoperable N=583, transcatheter aortic valve Intermediate risk N=1078) replacement in were enrolled in a inoperable, high-risk and randomised registry at 57 intermediate-risk patients in the USA and Canada and with aortic stenosis’ Eur received TAVR with SAPIEN 3 Heart J, 2016 4. Randomised Baron SJ Status Randomised Controlled Trial of August 2017 ‘Health Controlled Trial Benfits of Transcatheter vs 2032 intermediate-risk Surgical Aortic Valve patients with severe aortic Replacement in Patients stenosis at 57 centres who with Severe Aortic Stenosis underwent either TAVR or at Intermediate Surgical SAVR. Health related quality of Risk’ JAMA Cardiol. 2017;2 life was assessed at baseline, 1 (8):837-845 month, 1 year and 2 years. Note, reported results for the transfemoral cohort are most relevant to this application.
3. registry Kodali S et al ‘Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis’ Eur Heart J, 2016 Patients with severe, symptomatic AS (high surgical risk or inoperable N=583, Intermediate risk N=1078) were enrolled in a registry at 57 in the USA and Canada and received TAVR with SAPIEN 3 July 2016 4. Randomised Controlled Trial Baron SJ ‘Health Status Benfits of Transcatheter vs Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk’ JAMA Cardiol. 2017;2 (8):837-845 Randomised Controlled Trial of 2032 intermediate-risk patients with severe aortic stenosis at 57 centres who underwent either TAVR or SAVR. Health related quality of life was assessed at baseline, 1 month, 1 year and 2 years. Note, reported results for the transfemoral cohort are most relevant to this application. August 2017 randomised randomised